Umut Ulge - Neoleukin Therapeutics VP Devel
| NLTXDelisted Stock | USD 0.69 0.01 1.43% |
Insider
Umut Ulge is VP Devel of Neoleukin Therapeutics
| Phone | 855 226 6447 |
| Web | https://www.neoleukin.com |
Neoleukin Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1871) % which means that it has lost $0.1871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3788) %, meaning that it created substantial loss on money invested by shareholders. Neoleukin Therapeutics' management efficiency ratios could be used to measure how well Neoleukin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Neoleukin Therapeutics currently holds 12.07 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Neoleukin Therapeutics has a current ratio of 12.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neoleukin Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| James Brady | Spero Therapeutics | N/A | |
| AO FRACP | Assembly Biosciences | 65 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| David MD | Nuvation Bio | 54 | |
| Iraj Ali | Achilles Therapeutics PLC | 49 | |
| MBA MD | Spero Therapeutics | 43 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Solomon Langermann | NextCure | 64 | |
| Lieping MD | NextCure | 67 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| MD FACP | NextCure | 71 | |
| Michelle Doig | Nuvation Bio | 46 | |
| Mark Dudley | Instil Bio | N/A | |
| Sumita JD | Instil Bio | 50 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 |
Neoleukin Therapeutics Leadership Team
Elected by the shareholders, the Neoleukin Therapeutics' board of directors comprises two types of representatives: Neoleukin Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neoleukin. The board's role is to monitor Neoleukin Therapeutics' management team and ensure that shareholders' interests are well served. Neoleukin Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neoleukin Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Umut Ulge, VP Devel | ||
| MS MD, Chief Officer | ||
| Donna JD, Gen Legal | ||
| Carl Walkey, Sr Devel | ||
| Bill Arthur, VP Research | ||
| Sean Smith, VP Officer | ||
| Kamran Alam, CFO, Vice President - Finance | ||
| David Baker, Cofounder Board | ||
| Jonathan MD, President, CEO |
Neoleukin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neoleukin Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 45.58 % | |||
| Number Of Shares Shorted | 26.4 K | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |